Icon

LYNPARZA (nda206162)- (50MG)

OLAPARIB ASTRAZENECA
50MG
No No
2031-Aug-04 2019-Dec-19
2021-Dec-19 None
None No
Lynparza is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated for the treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated advanced ovarian cancer who have been treated with three or more prior lines of chemotherapy. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.
0 0 0
Total Other Developers None
Drugs with Suitability No
50MG ** ** - - -
NDA Sales Available Total Generic Sales Available
No 0
ANDA No Generic Co Manufacturer Name Operations Manufacturer Address Country

GenUs Advanced Search




Expired
to
Expired
to


Please contact contact@researchdelta.com to get more details.